CD20 positive T-cell lymphoma/leukemia: a rare entity with potential diagnostic pitfalls.
Ann Clin Lab Sci
; 37(3): 263-7, 2007.
Article
em En
| MEDLINE
| ID: mdl-17709692
ABSTRACT
Mature T-cell neoplasms are relatively uncommon, accounting for approximately 10% of all non-Hodgkin lymphomas. This category of hematopoietic neoplasms is clinically aggressive and shows a poor response to therapy and shortened survival. The antigen CD20 has long been thought to be a specific marker for B-cell lineage and has been used to help differentiate T-cell and B-cell neoplasms. We present two cases of a rare subset of T-cell leukemia/lymphoma having a unique immunophenotype, both being CD20+. The significance of CD20 antigen in T-cell lymphomas is yet to be determined, but may allow treatment with novel therapeutic agents (eg, rituximab, a recombinant anti-CD20 monoclonal antibody).
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia-Linfoma de Células T do Adulto
/
Biomarcadores Tumorais
/
Antígenos CD20
Tipo de estudo:
Diagnostic_studies
Limite:
Aged80
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Ann Clin Lab Sci
Ano de publicação:
2007
Tipo de documento:
Article